These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38097548)

  • 1. A cytosolic mutp53(E285K) variant confers chemoresistance of malignant melanoma.
    Dunsche L; Ivanisenko N; Riemann S; Schindler S; Beissert S; Angeli C; Kreis S; Tavassoli M; Lavrik I; Kulms D
    Cell Death Dis; 2023 Dec; 14(12):831. PubMed ID: 38097548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
    Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
    Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.
    Wei S; Wang H; Lu C; Malmut S; Zhang J; Ren S; Yu G; Wang W; Tang DD; Yan C
    J Biol Chem; 2014 Mar; 289(13):8947-59. PubMed ID: 24554706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant melanoma cells acquire resistance to DNA interstrand cross-linking chemotherapeutics by p53-triggered upregulation of DDB2/XPC-mediated DNA repair.
    Barckhausen C; Roos WP; Naumann SC; Kaina B
    Oncogene; 2014 Apr; 33(15):1964-74. PubMed ID: 23604128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1.
    Tong X; Xu D; Mishra RK; Jones RD; Sun L; Schiltz GE; Liao J; Yang GY
    J Biol Chem; 2021; 296():100098. PubMed ID: 33208462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
    Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
    Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response.
    Lin S; Yu L; Song X; Bi J; Jiang L; Wang Y; He M; Xiao Q; Sun M; Olopade OI; Zhao L; Wei M
    Cell Death Dis; 2019 Sep; 10(9):666. PubMed ID: 31511498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway.
    Parrales A; Ranjan A; Iyer SV; Padhye S; Weir SJ; Roy A; Iwakuma T
    Nat Cell Biol; 2016 Nov; 18(11):1233-1243. PubMed ID: 27775703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant p53 Gain of Function and Chemoresistance: The Role of Mutant p53 in Response to Clinical Chemotherapy.
    He C; Li L; Guan X; Xiong L; Miao X
    Chemotherapy; 2017; 62(1):43-53. PubMed ID: 27322648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.
    Kolukula VK; Sahu G; Wellstein A; Rodriguez OC; Preet A; Iacobazzi V; D'Orazi G; Albanese C; Palmieri F; Avantaggiati ML
    Oncotarget; 2014 Mar; 5(5):1212-25. PubMed ID: 24681808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.
    Patyka M; Sharifi Z; Petrecca K; Mansure J; Jean-Claude B; Sabri S
    Oncotarget; 2016 Sep; 7(37):60245-60269. PubMed ID: 27533246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 Family in Resistance to Targeted Therapy of Melanoma.
    Vlašić I; Horvat A; Tadijan A; Slade N
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.
    Cuddihy AR; Jalali F; Coackley C; Bristow RG
    Mol Cancer Ther; 2008 Apr; 7(4):980-92. PubMed ID: 18413811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degradation of mutant p53H175 protein by Zn(II) through autophagy.
    Garufi A; Pucci D; D'Orazi V; Cirone M; Bossi G; Avantaggiati ML; D'Orazi G
    Cell Death Dis; 2014 May; 5(5):e1271. PubMed ID: 24874727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Y220C mutated p53 by Foeniculum vulgare-derived phytochemicals as cancer therapeutics.
    Garg S; Singh J; Verma SR
    J Mol Model; 2023 Jan; 29(2):55. PubMed ID: 36700982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.
    Thangasamy T; Sittadjody S; Mitchell GC; Mendoza EE; Radhakrishnan VM; Limesand KH; Burd R
    BMC Cancer; 2010 Jun; 10():282. PubMed ID: 20540768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APE1/Ref-1 enhances DNA binding activity of mutant p53 in a redox-dependent manner.
    Cun Y; Dai N; Li M; Xiong C; Zhang Q; Sui J; Qian C; Wang D
    Oncol Rep; 2014 Feb; 31(2):901-9. PubMed ID: 24297337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
    Wu CE; Esfandiari A; Ho YH; Wang N; Mahdi AK; Aptullahoglu E; Lovat P; Lunec J
    Br J Cancer; 2018 Feb; 118(4):495-508. PubMed ID: 29235570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin.
    Avery-Kiejda KA; Zhang XD; Adams LJ; Scott RJ; Vojtesek B; Lane DP; Hersey P
    Clin Cancer Res; 2008 Mar; 14(6):1659-68. PubMed ID: 18310316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
    Shattuck-Brandt RL; Chen SC; Murray E; Johnson CA; Crandall H; O'Neal JF; Al-Rohil RN; Nebhan CA; Bharti V; Dahlman KB; Ayers GD; Yan C; Kelley MC; Kauffmann RM; Hooks M; Grau A; Johnson DB; Vilgelm AE; Richmond A
    Clin Cancer Res; 2020 Jul; 26(14):3803-3818. PubMed ID: 32234759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.